Overview

The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)

Status:
Completed
Trial end date:
2022-05-24
Target enrollment:
Participant gender:
Summary
Primary objective: To assess the potential effect of oral clarithromycin on the single dose pharmacokinetics of givinostat. Secondary objective: To assess the safety and tolerability of concomitant administration of givinostat plus clarithromycin.
Phase:
Phase 1
Details
Lead Sponsor:
Italfarmaco
Treatments:
Clarithromycin